NewsBenzinga이뮤텝, 고무적인 EFTISARC-NEO 2상 육종 생존 데이터 발표···에프티 + 키트루다 + 방사선 치료, 38명 환자 대상 12개월 무병생존율 81.1%, 국소재발 무발생률 94.1%, 원격전이 무발생률 86.2% 기록 이뮤텝, 고무적인 EFTISARC-NEO 2상 육종 생존 데이터 발표···에프티 + 키트루다 + 방사선 치료, 38명 환자 대상 12개월 무병생존율 81.1%, 국소재발 무발생률 94.1%, 원격전이 무발생률 86.2% 기록 Benzinga 2026.11.10 23:03 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide